Kusajili – Centralise les essais cliniques mondiaux

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).

• Pays Argentina, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Malaysia, Portugal, Romania, Serbia, Singapore, South Africa, Spain, Taiwan, Province of China, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Long-term OL Study of [S,S]-RBX in Patients With Fibromyalgia To evaluate the lon-term safety and tolerability of [S,S]-reboxetine in patients with fibromyalgia

• Pays Belgium, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, South Africa, Sweden, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia This study consists of a 4 week run-in period with a Ca based phosphate binder and 12 weeks treatment period by MCI-196 or placebo, (both on Ca based phosphate binder). During the treatment period, MCI-196 or placebo will be titrated every 3 weeks.

• Pays Czech Republic, France, Germany, Italy, Macedonia, the former Yugoslav Republic of, Poland, Serbia, South Africa, Spain, United Kingdom,
• Organes Aucun
• Spécialités Aucun